Completed NA INTERVENTIONAL 4-arm NCT00122447

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

CVD Risk and Prevention in Early Glucose Intolerance

Sponsor: Daiichi Sankyo

Conditions Impaired Glucose Tolerance Prediabetic State

Interventions Alpha lipoic acid Aspirin Olmesartan Placebo

Updated 11 times since 2017 Last updated: Nov 12, 2013 Started: May 31, 2005 Primary completion: May 31, 2011 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00122447, this NA trial focuses on Impaired Glucose Tolerance and Prediabetic State and remains completed. Sponsored by Daiichi Sankyo, it has been updated 11 times since 2005, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Mar 2024 — Jul 2024 [monthly]

Completed NA
Jan 2023 — Mar 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA

▶ Show 6 earlier versions

Dec 2021 — Dec 2022 [monthly]

Completed NA
Jan 2021 — Dec 2021 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Sep 2017 — Jun 2018 [monthly]

Completed NA
Feb 2017 — Sep 2017 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo
Emory University
National Center for Research Resources (NCRR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data source: Emory University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Atlanta, United States